U.K. researchers have shown that priming epicardial progenitor cells with RegeneRx’s thymosin beta4 peptide could promote the generation of mature cardiomyocytes after myocardial infarction. The findings point to an alternative to cell transplants to help decrease ischemic injury and increase cardiac repair after a heart attack.